N-acetylcysteine reduce the stress induced by cold storage of platelets: A potential way to extend shelf life of platelets

Handigund, Mallikarjun; Kim, Jeong Tae; Bae, Tae Won; Lee, Jaehyeon; Cho, Yong Gon

doi:10.1016/j.transci.2020.103039

Cited by 7 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was a slight improvement of platelet recovery 2 h post transfusion in the CPs with the NAC group. However, this improved recovery effect was diminished after 24 h post transfusion [34]. It is important to note that in this mouse study, CPs without NAC supplement were not tested due to aggregate formation in the storage bag.…”

Section: Reduction Of Cps Storage Lesion a Work In Progressmentioning

confidence: 86%

“…However, the platelets used in this experiment were stored in gas-permeable tubes instead of standardized storage containers, making it difficult to draw solid conclusions [33]. In a follow-up study, the effect of NAC on CPs post-transfusion recovery has been tested using the Prkdc scid mouse model [34]. There was a slight improvement of platelet recovery 2 h post transfusion in the CPs with the NAC group.…”

Section: Reduction Of Cps Storage Lesion a Work In Progressmentioning

confidence: 99%

See 1 more Smart Citation

The Missing Pieces to the Cold-Stored Platelet Puzzle

Zhao

Devine

2022

IJMS

View full text Add to dashboard Cite

Cold-stored platelets are making a comeback. They were abandoned in the late 1960s in favor of room-temperature stored platelets due to the need for longer post-transfusion platelet recoverability and survivability in patients with chronic thrombocytopenia. However, the current needs for platelet transfusions are rapidly changing. Today, more platelets are given to patients who are actively bleeding, such as ones receiving cardiac surgeries. It has been established that cold-stored platelets are more hemostatically effective, have reduced bacterial growth, and have longer potential shelf lives. These compelling characteristics led to the recent interest in bringing back cold-stored platelets to the blood systems. However, before reinstating cold-stored platelets in the clinics again, a thorough investigation of in vitro storage characteristics and in vivo transfusion effects is required. This review aims to provide an update on the recent research efforts into the storage characteristics and functions of cold-stored platelets using modern investigative tools. We will also discuss efforts made to improve cold-stored platelets to be a better and safer product. Finally, we will finish off with discussing the relevance of in vitro data to in vivo transfusion results and provide insights and directions for future investigations of cold-stored platelets.

show abstract

Section: Reduction Of Cps Storage Lesion a Work In Progressmentioning

confidence: 86%

Section: Reduction Of Cps Storage Lesion a Work In Progressmentioning

confidence: 99%

The Missing Pieces to the Cold-Stored Platelet Puzzle

Zhao

Devine

2022

IJMS

View full text Add to dashboard Cite

show abstract

“…GPIbα clustering is also thought to induce mitochondrial-dependent oxidative stress (reviewed in [80]). When stored in N-acetylcysteine, platelet storage damage induced by refrigeration is partly prevented as assessed in-vitro and in-vivo recovery and survival studies [81,82 ▪ ].…”

Section: Next-generation Platelet Productsmentioning

confidence: 99%

Novel blood derived hemostatic agents for bleeding therapy and prophylaxis

Hegde

Zheng

Cancelas

2022

Current Opinion in Hematology

View full text Add to dashboard Cite

Purpose of reviewHemorrhage is a major cause of preventable death in trauma and cancer. Trauma induced coagulopathy and cancer-associated endotheliopathy remain major therapeutic challenges. Early, aggressive administration of blood-derived products with hypothesized increased clotting potency has been proposed. A series of early- and late-phase clinical trials testing the safety and/or efficacy of lyophilized plasma and new forms of platelet products in humans have provided light on the future of alternative blood component therapies. This review intends to contextualize and provide a critical review of the information provided by these trials.Recent findingsThe beneficial effect of existing freeze-dried plasma products may not be as high as initially anticipated when tested in randomized, multicenter clinical trials. A next-generation freeze dried plasma product has shown safety in an early phase clinical trial and other freeze-dried plasma and spray-dried plasma with promising preclinical profiles are embarking in first-in-human trials. New platelet additive solutions and forms of cryopreservation or lyophilization of platelets with long-term shelf-life have demonstrated feasibility and logistical advantages.Summary:Recent trials have confirmed logistical advantages of modified plasma and platelet products in the treatment or prophylaxis of bleeding. However, their postulated increased potency profile remains unconfirmed.

show abstract